1. Home
  2. CAPR vs PDLB Comparison

CAPR vs PDLB Comparison

Compare CAPR & PDLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • PDLB
  • Stock Information
  • Founded
  • CAPR 2005
  • PDLB 1960
  • Country
  • CAPR United States
  • PDLB United States
  • Employees
  • CAPR N/A
  • PDLB N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • PDLB
  • Sector
  • CAPR Health Care
  • PDLB
  • Exchange
  • CAPR Nasdaq
  • PDLB Nasdaq
  • Market Cap
  • CAPR 324.6M
  • PDLB 328.3M
  • IPO Year
  • CAPR N/A
  • PDLB 2017
  • Fundamental
  • Price
  • CAPR $6.28
  • PDLB $14.86
  • Analyst Decision
  • CAPR Strong Buy
  • PDLB
  • Analyst Count
  • CAPR 8
  • PDLB 0
  • Target Price
  • CAPR $24.75
  • PDLB N/A
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • PDLB 33.5K
  • Earning Date
  • CAPR 08-11-2025
  • PDLB 10-29-2025
  • Dividend Yield
  • CAPR N/A
  • PDLB N/A
  • EPS Growth
  • CAPR N/A
  • PDLB 83.78
  • EPS
  • CAPR N/A
  • PDLB 0.71
  • Revenue
  • CAPR $13,392,150.00
  • PDLB $90,513,000.00
  • Revenue This Year
  • CAPR N/A
  • PDLB $10.97
  • Revenue Next Year
  • CAPR $6,061.53
  • PDLB $8.59
  • P/E Ratio
  • CAPR N/A
  • PDLB $20.85
  • Revenue Growth
  • CAPR N/A
  • PDLB 15.50
  • 52 Week Low
  • CAPR $3.98
  • PDLB $10.74
  • 52 Week High
  • CAPR $23.40
  • PDLB $15.06
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • PDLB 60.70
  • Support Level
  • CAPR $6.17
  • PDLB $13.96
  • Resistance Level
  • CAPR $7.30
  • PDLB $14.99
  • Average True Range (ATR)
  • CAPR 0.43
  • PDLB 0.32
  • MACD
  • CAPR -0.11
  • PDLB 0.03
  • Stochastic Oscillator
  • CAPR 4.53
  • PDLB 81.08

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About PDLB Ponce Financial Group Inc.

Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.

Share on Social Networks: